# Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
**Date:** 2026-02-23 01:15:00
**Company:** Novartis AG
**Ticker:** NVS
**Source URL:** https://www.globenewswire.com/news-release/2026/02/23/3242309/0/en/Novartis-presents-Rhapsido-remibrutinib-data-at-AAAAI-showing-potential-beyond-chronic-spontaneous-urticaria-CSU.html
---
[Accessibility: Skip TopNav](https://www.globenewswire.com/news-release/2026/02/23/3242309/0/en/Novartis-presents-Rhapsido-remibrutinib-data-at-AAAAI-showing-potential-beyond-chronic-spontaneous-urticaria-CSU.html#maincontainer)
[](https://www.globenewswire.com/)
- [Newsroom](https://www.globenewswire.com/newsroom)
- [Services](https://www.globenewswire.com/services)
- [Contact Us](https://insight.notified.com/globenewswire-contact-us?utm_medium=Website&utm_source=Contact%20Us&utm_campaign=Contact%20Us%20...
# Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
**Date:** 2026-02-23 01:15:00
**Company:** Novartis AG
**Ticker:** NVS
**Source URL:** https://www.globenewswire.com/news-release/2026/02/23/3242309/0/en/Novartis-presents-Rhapsido-remibrutinib-data-at-AAAAI-showing-potential-beyond-chronic-spontaneous-urticaria-CSU.html
---
[Accessibility: Skip TopNav](https://www.globenewswire.com/news-release/2026/02/23/3242309/0/en/Novartis-presents-Rhapsido-remibrutinib-data-at-AAAAI-showing-potential-beyond-chronic-spontaneous-urticaria-CSU.html#maincontainer)
[](https://www.globenewswire.com/)
- [Newsroom](https://www.globenewswire.com/newsroom)
- [Services](https://www.globenewswire.com/services)
- [Contact Us](https://insight.notified.com/globenewswire-contact-us?utm_medium=Website&utm_source=Contact%20Us&utm_campaign=Contact%20Us%20ENG)
- English
[Sign In](https://www.globenewswire.com/home/signin) [Register](https://portal.notified.com/en/registration)
# [](https://novartis.com/)
# Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
February 23, 2026 01:15 ET\| Source:
[Novartis Pharma AG](https://www.globenewswire.com/en/search/organization/Novartis%2520Pharma%2520%2520AG)FollowNovartis Pharma AG
* * *
Share
- * * *
- _Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented_
- _Phase II data evaluating safety and efficacy results of remibrutinib for treatment of peanut allergy to be featured in an oral session_
- _Phase III program in food allergy (FA) planned for H2 2026_
**Basel, February 23, 2026**– Novartis will present data from five key abstracts evaluating the highly selective oral Bruton’s tyrosine kinase inhibitor (BTKi) Rhapsido® (remibrutinib) in chronic spontaneous urticaria (CSU) and as an investigational therapy for peanut allergy at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia, PA, from February 27 to March 2, 2026. These presentations provide more evidence on the use of Rhapsido in CSU, as well as its potential in other indications and highlight Novartis commitment to addressing unmet needs in patients with immune-mediated diseases.
New analyses on the impact of Rhapsido on disease control and early symptom relief from the Phase III REMIX-1 and REMIX-2 trials in CSU will be presented. Additionally, the first presentation of Phase II FA data for remibrutinib, focusing on IgE‑mediated peanut allergy, will be featured in an oral session. Plans are in progress to begin the Phase III program in FA in 2026.
“These food allergy (FA) data further strengthen the evidence supporting remibrutinib as a novel, well-tolerated, oral option for patients with allergic and immune-mediated diseases, complementing the recent FDA approval in chronic spontaneous urticaria (CSU) and underscoring its broader therapeutic potential,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. "Our priority is advancing therapies for patients who have few alternatives and expanding the reach of innovative medicines to transform care across multiple, high-need disease areas."
Regulatory reviews for remibrutinib for the treatment of CSU are underway in several regions, including the European Union and Japan.
In addition to FA, remibrutinib is in clinical development for chronic inducible urticaria (CIndU) and hidradenitis suppurativa (HS). FDA submission for remibrutinib in symptomatic dermographism, the most prevalent type of CIndU, was completed in Q4 2025 _._ Additionally, positive topline results were announced for the remaining two arms of the CIndU Phase III RemIND trial. In the coming months, the full data set will be submitted to health authorities globally, and the RemIND trial findings will be presented at upcoming medical congresses.
**Abstracts accepted by AAAAI include:**
| | |
| --- | --- |
| **Abstract Title** | **Abstract Number/Presentation Details** |
| Efficacy and safety of remibrutinib, a Bruton’s tyrosine kinase inhibitor, for individuals with IgE-mediated peanut allergy | Abstract #563<br>Oral Presentation<br>Saturday, February 28<br>2:45-2:55 PM EST |
| Remibrutinib Decreases Urticaria Disease Activity Leading To Improved Disease Control: An Analysis From The REMIX-1/-2 studies | Abstract #822<br>Poster <br>Sunday, March 1<br>3:30-5:00 PM EST |
| Remibrutinib Provides Fast Symptom Relief Within the First Week of Treatment in Chronic Spontaneous Urticaria, as Measured by Daily Urticaria Activity Score: Pooled REMIX-1/-2 Studies | Abstract #039<br>Poster <br>Friday, February 27<br>2:45-3:45 PM EST |
| Patients with Chronic Spontaneous Urticaria (CSU) in the US (United States): Health Care Resource Utilization (HCRU) by Level of Disease Control | Abstract #021 <br>Poster <br>Friday, February 27<br>2:45-3:45 PM EST |
| A Novel Panel of Autoantibodies May Assist In The Molecular Diagnosis of CSU | Abstract #022 <br>Poster <br>Friday, February 27<br>2:45-3:45 PM EST |
| | |
**About Novartis Immunology**
At Novartis, we’re advancing bold science with the goal of bringing relief and a renewed sense of hope to people living with autoimmune diseases. Building on our legacy of first-in-class innovation across rheumatology, dermatology and allergy, and a diverse industry-leading pipeline, we’re committed to shaping what’s next in Immunology.
For full prescribing information, including approved indications and important safety information about marketed products, please visit [https://www.novartis.com/about/products](https://www.novartis.com/about/products "")
**Disclaimer**
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
**About Novartis**
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide.
Reimagine medicine with us: Visit us at [**https://www.novartis.com**](https://www.novartis.com/ "") and connect with us on [**LinkedIn**](https://www.linkedin.com/company/novartis/ ""), [**Facebook**](https://www.facebook.com/novartis/ ""), [**X/Twitter**](https://twitter.com/Novartis "") and [**Instagram**](https://instagram.com/novartis?igshid=MzRlODBiNWFlZA==__;!!N3hqHg43uw!pjp8z253J5NjaOYrW65UbAAlHeHRdQ-w0m4ezZxEQEl0ptafXN2M99VRIk39pf49PAc8NbK93Pxp3uaSBQkAf8oEnzWXG8Sk$ "").
\# # #
| | | |
| --- | --- | --- |
| **Novartis Media Relations**<br>E-mail: [media.relations@novartis.com](mailto:media.relations@novartis.com "media.relations@novartis.com") | | |
| **Novartis Investor Relations**<br>Central investor relations line: +41 61 324 7944<br>E-mail: [investor.relations@novartis.com](mailto:investor.relations@novartis.com "investor.relations@novartis.com") | |
* * *
## Tags
[Media Release](https://www.globenewswire.com/en/search/tag/media%2520release "Media Release")[Reimagine Medicine](https://www.globenewswire.com/en/search/tag/reimagine%2520medicine "Reimagine Medicine")[Innovation](https://www.globenewswire.com/en/search/tag/innovation "Innovation")[Chronic Illness](https://www.globenewswire.com/en/search/tag/chronic%2520illness "Chronic Illness")
### Attachments
[](https://ml-eu.globenewswire.com/Resource/Download/dfb696b7-1b58-416d-808d-eefc2043de7a) Media release (PDF)...
GlobeNewswire
Company ProfileNovartis Pharma AGIndustry: PharmaceuticalsWebsite:
[https://novartis.com](https://novartis.com/)
Press Release Actions
- [Print](https://www.globenewswire.com/news-release/2026/02/23/3242309/0/en/Novartis-presents-Rhapsido-remibrutinib-data-at-AAAAI-showing-potential-beyond-chronic-spontaneous-urticaria-CSU.html?print=1)
- [Download PDF](https://www.globenewswire.com/news-release/2026/02/23/3242309/0/en/Novartis-presents-Rhapsido-remibrutinib-data-at-AAAAI-showing-potential-beyond-chronic-spontaneous-urticaria-CSU.html?pdf=1)
- [Subscribe via RSS](https://www.globenewswire.com/rssfeed/organization/ApPC3aRBom1jeiovES24_w==)
- [Subscribe via ATOM](https://www.globenewswire.com/atomfeed/organization/ApPC3aRBom1jeiovES24_w==)
- [Javascript](https://www.globenewswire.com/JSWidget/organization/pwirdc8wK6GuHGKqBL1s1w%3d%3d)
## Recommended Reading
- February 27, 2026 09:00 ET\|Source: [Novartis Pharma AG](https://www.globenewswire.com/en/search/organization/Novartis%2520Pharma%2520%2520AG)
[Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy](https://www.globenewswire.com/news-release/2026/02/27/3246557/0/en/Novartis-successfully-completes-acquisition-of-Avidity-Biosciences-strengthening-late-stage-neuroscience-pipeline-and-advancing-xRNA-strategy.html)
Adds Avidity’s differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipelinePotentially unlocks...
[Read More](https://www.globenewswire.com/news-release/2026/02/27/3246557/0/en/Novartis-successfully-completes-acquisition-of-Avidity-Biosciences-strengthening-late-stage-neuroscience-pipeline-and-advancing-xRNA-strategy.html)
- February 27, 2026 06:29 ET\|Source: [Novartis Pharma AG](https://www.globenewswire.com/en/search/organization/Novartis%2520Pharma%2520%2520AG)
[Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)](https://www.globenewswire.com/news-release/2026/02/27/3246401/0/en/Novartis-receives-positive-CHMP-opinion-for-remibrutinib-in-chronic-spontaneous-urticaria-CSU.html)
Remibrutinib, a highly selective oral BTKi, has potential to be first targeted therapy approved for CSU in Europe Improvements with remibrutinib observed as early as Week 1 in REMIX 1 & 2, with...
[Read More](https://www.globenewswire.com/news-release/2026/02/27/3246401/0/en/Novartis-receives-positive-CHMP-opinion-for-remibrutinib-in-chronic-spontaneous-urticaria-CSU.html)
[View More News](https://www.globenewswire.com/en/newsroom)
## Explore
Previous
[](https://www.globenewswire.com/news-release/2026/03/03/3248885/0/en/Toll-Brothers-Announces-Final-Opportunity-to-Own-a-Luxury-Townhome-at-Mira-Vista-in-San-Diego-California.html)
March 03, 2026 15:57 ET
[Toll Brothers Announces Final Opportunity to Own a...](https://www.globenewswire.com/news-release/2026/03/03/3248885/0/en/Toll-Brothers-Announces-Final-Opportunity-to-Own-a-Luxury-Townhome-at-Mira-Vista-in-San-Diego-California.html "Toll Brothers...")
[](https://www.globenewswire.com/news-release/2026/03/03/3248862/0/en/Witte-Museum-Brings-90s-Nostalgia-to-Life-with-The-Robot-Zoo.html)
March 03, 2026 15:20 ET
[Witte Museum Brings '90s Nostalgia to Life with Th...](https://www.globenewswire.com/news-release/2026/03/03/3248862/0/en/Witte-Museum-Brings-90s-Nostalgia-to-Life-with-The-Robot-Zoo.html "Witte Museum Brings...")
[](https://www.globenewswire.com/news-release/2026/03/03/3248861/0/en/SUCCESS-Releases-Digital-Edition-Dedicated-to-the-Power-of-Coaching.html)
March 03, 2026 15:18 ET
[SUCCESS® Releases Digital Edition Dedicated to the...](https://www.globenewswire.com/news-release/2026/03/03/3248861/0/en/SUCCESS-Releases-Digital-Edition-Dedicated-to-the-Power-of-Coaching.html "SUCCESS® Releases...")
[](https://www.globenewswire.com/news-release/2026/03/03/3248950/0/en/Kraken-Robotics-Announces-Signing-of-Strategic-Acquisition-to-Expand-Global-Maritime-Capabilities.html)
March 03, 2026 16:18 ET
[Kraken Robotics Announces Signing of Strategic Acq...](https://www.globenewswire.com/news-release/2026/03/03/3248950/0/en/Kraken-Robotics-Announces-Signing-of-Strategic-Acquisition-to-Expand-Global-Maritime-Capabilities.html "Kraken Robotics...")
[](https://www.globenewswire.com/news-release/2026/03/03/3248903/0/en/Coherent-Executives-to-Showcase-Thought-Leadership-at-OFC-CTO-Julie-Eng-to-Deliver-the-Plenary-Session.html)
March 03, 2026 16:05 ET
[Coherent Executives to Showcase Thought Leadership...](https://www.globenewswire.com/news-release/2026/03/03/3248903/0/en/Coherent-Executives-to-Showcase-Thought-Leadership-at-OFC-CTO-Julie-Eng-to-Deliver-the-Plenary-Session.html "Coherent Executives...")
[](https://www.globenewswire.com/news-release/2026/03/03/3248885/0/en/Toll-Brothers-Announces-Final-Opportunity-to-Own-a-Luxury-Townhome-at-Mira-Vista-in-San-Diego-California.html)
March 03, 2026 15:57 ET
[Toll Brothers Announces Final Opportunity to Own a...](https://www.globenewswire.com/news-release/2026/03/03/3248885/0/en/Toll-Brothers-Announces-Final-Opportunity-to-Own-a-Luxury-Townhome-at-Mira-Vista-in-San-Diego-California.html "Toll Brothers...")
[](https://www.globenewswire.com/news-release/2026/03/03/3248862/0/en/Witte-Museum-Brings-90s-Nostalgia-to-Life-with-The-Robot-Zoo.html)
March 03, 2026 15:20 ET
[Witte Museum Brings '90s Nostalgia to Life with Th...](https://www.globenewswire.com/news-release/2026/03/03/3248862/0/en/Witte-Museum-Brings-90s-Nostalgia-to-Life-with-The-Robot-Zoo.html "Witte Museum Brings...")
[](https://www.globenewswire.com/news-release/2026/03/03/3248861/0/en/SUCCESS-Releases-Digital-Edition-Dedicated-to-the-Power-of-Coaching.html)
March 03, 2026 15:18 ET
[SUCCESS® Releases Digital Edition Dedicated to the...](https://www.globenewswire.com/news-release/2026/03/03/3248861/0/en/SUCCESS-Releases-Digital-Edition-Dedicated-to-the-Power-of-Coaching.html "SUCCESS® Releases...")
[](https://www.globenewswire.com/news-release/2026/03/03/3248950/0/en/Kraken-Robotics-Announces-Signing-of-Strategic-Acquisition-to-Expand-Global-Maritime-Capabilities.html)
March 03, 2026 16:18 ET
[Kraken Robotics Announces Signing of Strategic Acq...](https://www.globenewswire.com/news-release/2026/03/03/3248950/0/en/Kraken-Robotics-Announces-Signing-of-Strategic-Acquisition-to-Expand-Global-Maritime-Capabilities.html "Kraken Robotics...")
[](https://www.globenewswire.com/news-release/2026/03/03/3248903/0/en/Coherent-Executives-to-Showcase-Thought-Leadership-at-OFC-CTO-Julie-Eng-to-Deliver-the-Plenary-Session.html)
March 03, 2026 16:05 ET
[Coherent Executives to Showcase Thought Leadership...](https://www.globenewswire.com/news-release/2026/03/03/3248903/0/en/Coherent-Executives-to-Showcase-Thought-Leadership-at-OFC-CTO-Julie-Eng-to-Deliver-the-Plenary-Session.html "Coherent Executives...")
[](https://www.globenewswire.com/news-release/2026/03/03/3248885/0/en/Toll-Brothers-Announces-Final-Opportunity-to-Own-a-Luxury-Townhome-at-Mira-Vista-in-San-Diego-California.html)
March 03, 2026 15:57 ET
[Toll Brothers Announces Final Opportunity to Own a...](https://www.globenewswire.com/news-release/2026/03/03/3248885/0/en/Toll-Brothers-Announces-Final-Opportunity-to-Own-a-Luxury-Townhome-at-Mira-Vista-in-San-Diego-California.html "Toll Brothers...")
[](https://www.globenewswire.com/news-release/2026/03/03/3248862/0/en/Witte-Museum-Brings-90s-Nostalgia-to-Life-with-The-Robot-Zoo.html)
March 03, 2026 15:20 ET
[Witte Museum Brings '90s Nostalgia to Life with Th...](https://www.globenewswire.com/news-release/2026/03/03/3248862/0/en/Witte-Museum-Brings-90s-Nostalgia-to-Life-with-The-Robot-Zoo.html "Witte Museum Brings...")
[](https://www.globenewswire.com/news-release/2026/03/03/3248861/0/en/SUCCESS-Releases-Digital-Edition-Dedicated-to-the-Power-of-Coaching.html)
March 03, 2026 15:18 ET
[SUCCESS® Releases Digital Edition Dedicated to the...](https://www.globenewswire.com/news-release/2026/03/03/3248861/0/en/SUCCESS-Releases-Digital-Edition-Dedicated-to-the-Power-of-Coaching.html "SUCCESS® Releases...")
Next
About Us
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases, financial disclosures and multimedia content to media, investors, and consumers worldwide.
Global News
- [English](https://www.globenewswire.com/newsroom)
- [Français](https://www.globenewswire.com/fr/newsroom)
- [Deutsch](https://www.globenewswire.com/de/newsroom)
Newswire Distribution Network & Management
- [Home](https://www.globenewswire.com/)
- [Newsroom](https://www.globenewswire.com/newsroom)
- [RSS Feeds](https://www.globenewswire.com/rss/list)
- [Notified](https://www.notified.com/)
- [Legal](https://www.notified.com/privacy)
- [Contact us](https://insight.notified.com/globenewswire-contact-us?utm_medium=Website&utm_source=Contact%20Us&utm_campaign=Contact%20Us%20ENG)
- [Resources](https://www.notified.com/resources)
© 2026 Digital Media Innovations, LLC. All rights reserved.
[GlobeNewswire Linkedin](https://www.linkedin.com/company/1006947 "GlobeNewswire Linkedin") [Notified Twitter](https://twitter.com/Notified "Notified Twitter")
;
[Français](https://www.globenewswire.com/fr/news-release/2026/02/23/3242309/0/en/Novartis-presents-Rhapsido-remibrutinib-data-at-AAAAI-showing-potential-beyond-chronic-spontaneous-urticaria-CSU.html) [Deutsch](https://www.globenewswire.com/de/news-release/2026/02/23/3242309/0/en/Novartis-presents-Rhapsido-remibrutinib-data-at-AAAAI-showing-potential-beyond-chronic-spontaneous-urticaria-CSU.html)